PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-100.73%
Negative net income growth while Drug Manufacturers - Specialty & Generic median is 13.53%. Seth Klarman would suspect a firm-specific problem if peers maintain profit growth.
4.09%
D&A growth of 4.09% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question intangible or new expansions driving that cost difference.
16.49%
Deferred tax growth of 16.49% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would see a difference that might matter for future cash flow if significant.
-1.73%
SBC declines yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a near-term advantage in less dilution unless new hires are needed.
-65.11%
Working capital is shrinking yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see an advantage if sales remain robust.
113.18%
AR growth of 113.18% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or more relaxed credit if revenue is not matching it.
-363.12%
Inventory shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a working capital edge if sales hold up.
60.91%
AP growth of 60.91% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or credit policies affecting the difference.
-131.61%
Other WC usage shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see an advantage if top-line is stable or growing.
990.31%
A moderate rise while Drug Manufacturers - Specialty & Generic median is negative at -36.98%. Peter Lynch might see peers cleaning up intangible or one-time items more aggressively.
47.13%
CFO growth of 47.13% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would see a small edge that may compound with consistent execution.
-65.54%
CapEx declines yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would note a short-term FCF advantage if revenue is stable.
99.91%
Acquisition growth of 99.91% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or partial deals fueling that difference.
-161.81%
Investment purchases shrink yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a short-term cash advantage if no high-return opportunities are missed.
-68.75%
We liquidate less yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a firm-specific hold strategy unless missed gains exist.
1734.95%
Growth of 1734.95% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss questions intangible or special projects explaining that difference.
-64.46%
Reduced investing yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman sees potential advantage in near-term liquidity if revenue remains stable.
91.33%
Debt repayment growth of 91.33% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss wonders if expansions or a shift in capital structure drive that difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.